|
ATCC
human hepatocyte cell line hepg2 ![]() Human Hepatocyte Cell Line Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human hepatocyte cell line hepg2/product/ATCC Average 99 stars, based on 1 article reviews
human hepatocyte cell line hepg2 - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
hepg2 human hepatocyte cell line ![]() Hepg2 Human Hepatocyte Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/hepg2 human hepatocyte cell line/product/ATCC Average 99 stars, based on 1 article reviews
hepg2 human hepatocyte cell line - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
human hepatocyte carcinoma hepg2 cells ![]() Human Hepatocyte Carcinoma Hepg2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human hepatocyte carcinoma hepg2 cells/product/ATCC Average 99 stars, based on 1 article reviews
human hepatocyte carcinoma hepg2 cells - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
human hepatocyte carcinoma cell line hepg2 ![]() Human Hepatocyte Carcinoma Cell Line Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human hepatocyte carcinoma cell line hepg2/product/ATCC Average 99 stars, based on 1 article reviews
human hepatocyte carcinoma cell line hepg2 - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
Procell Inc
human hepatocyte line hepg2 cells ![]() Human Hepatocyte Line Hepg2 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human hepatocyte line hepg2 cells/product/Procell Inc Average 86 stars, based on 1 article reviews
human hepatocyte line hepg2 cells - by Bioz Stars,
2026-05
86/100 stars
|
Buy from Supplier |
Journal: Frontiers in Pharmacology
Article Title: Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17
doi: 10.3389/fphar.2026.1804415
Figure Lengend Snippet: MiR-300-3p was decreased in the livers of MAFLD mice and FFA-induced HepG2 cells. (A) MiR-300-3p was decreased in the livers of MAFLD mice. (B) MiR-300-3p was downregulated in the FFA-induced HepG2 cells. (C) MiR-300-3p was downregulated in HepG2 cells successfully. (D) MiR-300-3p was overexpressed in HepG2 cells successfully. Data in (A–D) are means±SDs (n = 3). *P < 0.05, **P < 0.01. NC, Healthy control; OC, over-expression control; IC, inhibition control.
Article Snippet: The
Techniques: Control, Over Expression, Inhibition
Journal: Frontiers in Pharmacology
Article Title: Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17
doi: 10.3389/fphar.2026.1804415
Figure Lengend Snippet: Downregulation of miR-300-3p promotes FFA-induced lipid accumulation and hepatic inflammation in HepG2 cells. (A) The experimental flow of the MAFLD cell model construction and miR-300-3p mimics, miR-300-3p inhibitors and as well as corresponding scrambled controls transfection in HepG2 cells. (B,C) Intercellular TG contents in miR-300-3p -inhibited and -overexpressing in HepG2 cells. (D) Oil Red O staining (400×) and the relative areas of lipid droplets in miR-300-3p-inhibited and -overexpressing in HepG2 cells. (E,F) mRNA levels of FASN, SREBP-1c, IL-6, IL-2 and TNF-αin miR-300-3p -inhibited and -overexpressing in HepG2 cells. (G) Protein levels of FASN, SREBP-1c and TNF-α in miR-300-3p -inhibited and -overexpressing in HepG2 cells. Data in (B,C) and (E–G) are means±SDs (n = 3). *P < 0.05, **P < 0.01, *** P < 0.001, **** P < 0.0001. OC, over-expression control; IC, inhibition control.
Article Snippet: The
Techniques: Transfection, Staining, Over Expression, Control, Inhibition
Journal: Frontiers in Pharmacology
Article Title: Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17
doi: 10.3389/fphar.2026.1804415
Figure Lengend Snippet: Downregulation of miR-300-3p induces apoptosis in HepG2 cells to promote it. (A,B) The apoptosis rate in miR-300-3p -inhibited and -overexpressing in HepG2 cells. (C) mRNA levels of Bax, Bcl-2 and Caspase-3 in miR-300-3p -inhibited and -overexpressing in HepG2 cells. (D) Protein levels of Bax, Bcl-2 and Caspase-3 in miR-300-3p -overexpressing and -inhibited in HepG2 cells. Data in (A–D) are means±SDs (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. OC, over-expression control; IC, inhibition control.
Article Snippet: The
Techniques: Over Expression, Control, Inhibition
Journal: Frontiers in Pharmacology
Article Title: Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17
doi: 10.3389/fphar.2026.1804415
Figure Lengend Snippet: MiR-300-3p regulates STX17 in HepG2 cells. (A,B) GO enrichment analysis (Biological Process category) and KEGG enrichment analysis diagrams of sixteen predicted target genes of miR-300-3p. (C) The predicted binding sites between miR-300-3p and STX17 were putatively identified via the TargetScan database. (D) Dual-luciferase reporter assay (DLRA) in HepG2 cells validated that STX17 is a direct target gene of miR-300-3p. (E,F) The mRNA and protein expression levels of STX17 in HepG2 cells with miR-300-3p inhibition or overexpression. Data in (A–D) are means±SDs (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. OC, overexpression control; IC, inhibition control.
Article Snippet: The
Techniques: Binding Assay, Luciferase, Reporter Assay, Expressing, Inhibition, Over Expression, Control
Journal: Frontiers in Pharmacology
Article Title: Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17
doi: 10.3389/fphar.2026.1804415
Figure Lengend Snippet: P62 and LC3-II in miR-300-3p -inhibited and -overexpressing in HepG2 cells. (A) The protein levels of P62 and LC3-II in miR-300-3p -inhibited and -overexpressing in HepG2 cells. (B) P62 and LC3-II in miR-300-3p -inhibited and -overexpressing by Immunofluorescence assay. Data in (A-D) are means±SDs (n = 3). *P < 0.05, **P < 0.01,***P < 0.001,****P < 0.0001. OC, overexpression control; IC, inhibition control.
Article Snippet: The
Techniques: Immunofluorescence, Over Expression, Control, Inhibition
Journal: Frontiers in Pharmacology
Article Title: Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17
doi: 10.3389/fphar.2026.1804415
Figure Lengend Snippet: MiR-300-3p promoted autophagy by regulating STX17, reduces lipid accumulation, inflammatory response, and decreases hepatocyte apoptosis. (A) STX17 was inhibited or overexpressed in HepG2 cells successfully. (B) Protein levels of FASN, SREBP-1c and TNF-αin STX17 -inhibited and -overexpressing in HepG2 cells. (C,D) Intercellular TG contents in STX17-inhibited and -overexpressing in HepG2 cells. (E) Oil Red O staining (400×) and relative areas of lipid droplets in STX17-inhibited and -STX17 in HepG2 cells. (F) Protein levels of Bax, Capase-3 and Bcl-2 in STX17 -inhibited and -overexpressing in HepG2 cells. Data in (A–D) and (F) are means±SDs (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. OC, miR-300-3p overexpression control; IC,miR-300-3p inhibition control; Control, STX17-overexpression control or STX17-inhibition control; Si-STX17, STX17-inhibition; Over-STX17, STX17-overexpression.
Article Snippet: The
Techniques: Staining, Over Expression, Control, Inhibition
Journal: Frontiers in Pharmacology
Article Title: Downregulation of microRNA-300-3p promotes steatosis-to-MASH progression by regulating STX17
doi: 10.3389/fphar.2026.1804415
Figure Lengend Snippet: P62, LC3-II in STX17-inhibited and -overexpressing in HepG2 cells. (A) Protein levels of P62, LC3-II in STX17-inhibited and -overexpressing in HepG2 cells. (B) P62 and LC3-II in STX17-inhibited and -overexpressing by Immunofluorescence assay. Data in (A-D) are means±SDs (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. OC, overexpression control; IC, inhibition control.
Article Snippet: The
Techniques: Immunofluorescence, Over Expression, Control, Inhibition
Journal: Biotechnology Reports
Article Title: Insulin Resistance, Anti-inflammatory, and Antioxidant In vitro Activity of Heterologously Expressed Arenin from Dryophytes arenicolor
doi: 10.1016/j.btre.2026.e00947
Figure Lengend Snippet: In vitro modulation of hepatic insulin resistance by arenin in hepatic insulin-resistant (HepG2) cells . Arenin concentrations (3.90–1000 µg/mL) were incubated for 5 h in hepatic insulin-resistant cells. Negative control (N) cells were cultured in the absence of insulin, whereas insulin-resistant (IR) control cells were cultured in the presence of insulin. Rosiglitazone (ROSI) at 10 μM (3.57 µg/mL) was used as the positive reference control. Different letters abc indicate statistical differences between concentrations analyzed using Tukey test ( p < 0.05).
Article Snippet:
Techniques: In Vitro, Incubation, Negative Control, Cell Culture, Control